Inari Medical price target lowered to $63 from $65 at Baird

Baird analyst David Rescott lowered the firm’s price target on Inari Medical to $63 from $65 and keeps an Outperform rating on the shares. The firm said they delivered another beat/raise with revenue growth and reiterated profit expectations while noting 4Q catalysts should provide a source of upside and international revenue increasing contribution.